Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)

Anindita Chakraborty a, Dick C. Chan a, Katrina L. Ellis a, Jing Pang a, Wendy Barnett b, Ann Marie Woodward b, Mary Vorster b, Richard Norman c, Eric K. Moses d, Gerald F. Watts a,b,*

a Medical School, University of Western Australia, Perth, Western Australia, Australia
b Lipid Disorders Clinic, Department of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia
c School of Population Health, Curtin University, Perth, Western Australia, Australia
d Mensies Institute for Medical Research, University of Tasmania, Tasmania, Australia

1. Introduction

Epidemiological and genetic studies confirm evidence that elevated plasma lipoprotein(a) (Lp(a)) concentration results in atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease [1–3]. Lp(a) has inflammatory, oxidative, and anti-fibrinolytic properties [4,5]. Current guidelines propose that plasma Lp(a) levels ≥50 mg/dL are a risk-enhancing factor for ASCVD [6–9]. However, elevated Lp(a) is not routinely tested in clinical practice.

Lp(a) consists of a low-density lipoprotein (LDL)-particle covalently linked to a highly polymorphic apolipoprotein(a) [apo(a)] moiety [10]. Lp(a) concentrations are 70–90% heritable and determined by the LPA gene locus [4,5,10]. The plasma concentrations of Lp(a) tend to remain relatively constant throughout life [6]. Expert guidelines recommend testing for elevated Lp(a) in individuals at intermediate or high risk of ASCVD, and in patients with a personal or family history of premature coronary artery disease (CAD), including those with familial hypercholesterolemia (FH) [6–9].

Genetic cascade testing is a cost-effective strategy for detecting FH in close relatives of affected index cases [11]. Cascade testing for elevated Lp(a) is also a feasible and effective approach for identifying new cases of elevated Lp(a) during genetic cascade testing for FH [12]. No studies have, however, been reported in families without FH.

In the present investigation, we examined the hypothesis, based on...
previous studies in FH [12,13], that cascade testing is effective in detecting new cases of elevated Lp(a) among close relatives of probands with elevated Lp(a) concentration and dyslipidemias other than FH. The primary objective was to describe the yield of detecting elevated Lp(a) from cascade testing relatives of probands with common dyslipidemias, other than FH, presenting to a lipid clinic. Secondary objectives were to describe the spectrum of cardiovascular factors and the initiation of lipid-lowering therapy (LLT) in affected relatives, as well as the experience of screeners of the cascade testing process.

2. Methods

We report on a selected group of patients who participated in an Lp (a) cascade testing program carried out in the Lipid Disorders Clinic between 2016 and 2021. Affected probands with Lp(a) ≥100 mg/dL were identified from patients with phenotypic dyslipidemias [e.g., familial combined hyperlipidemia (FCHL) and common hypercholesterolemia (CH)] with no detectable FH gene variants, referred by general practitioners (GP), cardiologists and other specialists to the clinic. The selection of a cut-off Lp(a) concentration ≥100 mg/dL was based on a pilot study showing that the detection rate for relatives with elevated Lp (a) at this level was significantly higher than those with Lp(a) concentration between 50 and 99 mg/dL (Fig. 1 in online supplementary material; 88.9% vs 40.0%, P = 0.003). Accordingly, 83 probands with plasma concentration ≥100 mg/dL and their relatives agreed to participate in the cascade testing program, with at least one family member being tested for Lp(a). A total of 182 relatives, including children and adolescents (n = 31), were tested for elevated Lp(a) (defined as ≥50 mg/dL) and their clinical details, including cardiovascular risk factors were detailed. Details of the cascade testing protocol, assessment of patient-reported experience, clinical definition, biochemical and statistical analyses are given in supplementary material. The study was approved by the Royal Perth Hospital (Quality Activity 17,496) and University of Western Australia Human Research Ethics office RA/4/20/5553.

3. Results

3.1. Subject characteristics

The demographic, clinical and biochemical characteristics of the 83 probands and 151 adult relatives are described in Table 1. Compared with adult relatives, probands were older (P < 0.01), more likely to be male (P < 0.05) and had a higher prevalence of CAD (P < 0.001), smoking (P < 0.01) and hypertension (P < 0.001). The proportion of receiving cholesterol-lowering therapy (statin and/or ezetimibe) was significantly higher in probands than relatives. Plasma concentrations of pre-treatment cholesterol, triglycerides, non-HDL-cholesterol, LDL-

![Figure 1](image-url)
cholesterol and apolipoprotein B, as well as Lp(a), were significantly higher in probands than in adult relatives ($P < 0.001$ for all). There were no statistically significant differences in body mass index (BMI), plasma glucose concentration and estimated glomerular filtration rate (eGFR) between probands and adult relatives. Among subjects without a personal history of CAD (Table 1), the proportion with low risk of ASCVD was greater in relatives than probands ($P < 0.01$), the proportion with moderate risk of ASCVD being conversely greater in relatives ($P < 0.01$).

Compared with adults, children and adolescents tested for elevated Lp(a) ($n = 31$) were more likely to be male (62%), non-obese (BMI 22.0 ± 4.2 kg/m$^2$) and normolipidemic (total cholesterol 4.7 ± 0.8 mmol/L, triglycerides 0.9 [0.7–1.1 mmol/L] and LDL-cholesterol 3.2 ± 0.6 mmol/L); none had a personal history of CAD, hypertension and type 2 diabetes, or were on cholesterol-lowering medication.

### 3.2. Outcome of cascade testing for elevated Lp(a)

Fig. 1 shows the proportion of relatives with elevated Lp(a) ($\geq 50$ mg/dL) according to the Lp(a) concentrations of probands. Overall, elevated Lp(a) was found in 68.1% of relatives, 32.9% having Lp(a) between 50 and 99 mg/dL and 35.2% $\geq 100$ mg/dL (Fig. 1A). The proportion of relatives detected with elevated Lp(a) was significantly greater (81.1% vs 55.5%; $P = 0.001$) when tested from probands with Lp(a) $> 150$ mg/dL (Fig. 1B) compared with probands with Lp(a) between 100 and 150 mg/dL (Fig. 1C). The proportion of first- and second-degree relatives of probands cascade tested for high Lp(a) were 94.0% ($n = 171$) and 6.0% ($n = 11$), respectively. Of the 11 second-degree relatives, 6 were first-degree relatives from an index case with elevated Lp(a) and the others we tested for practical and preferential reasons as second-degree relatives of the probands.

One new case of elevated Lp(a) $\geq 50$ mg/dL was identified for every 1.5 relatives tested and 1 new case of elevated Lp(a) $\geq 100$ mg/dL for every 2.8 relatives tested (see Central Illustration). One new case of elevated Lp(a) $\geq 50$ mg/dL was also identified for every 1.8 relatives with probands having Lp(a) between 100 and 150 mg/dL and 1 new case for every 1.2 tested with probands Lp(a) concentration $> 150$ mg/dL. The Lp(a) concentration of probands was a significant positive predictor of the probability of detecting a relative with elevated Lp(a) (odds ratio 1.45; 95% CI 1.19-1.81 for each 25 mg/dL increment of plasma Lp(a); $P < 0.001$).

Fig. 2 shows the pedigrees of three selected families in whom the yield of detection of elevated Lp(a) was particularly high. In family 38 (in which the proband had a very high Lp(a) at 233 mg/dL), all ten relatives tested were found to have Lp(a) $> 50$ mg/dL, with 5 having Lp(a) $> 100$ mg/dL. In family 45, all four relatives tested were identified with Lp(a) $\geq 50$ mg/dL. Of six relatives tested in family 77, three were identified with Lp(a) $\geq 50$ mg/dL, with two $\geq 100$ mg/dL.

### 3.3. Cost estimation

The cost of Lp(a) assays for the 182 relatives was estimated to be A$3276. This cost was less than the estimated cost of staff time associated with contacting relatives, booking appointments, nurse review of relatives, consultant review, and counselling regarding cascade testing of relatives. The total staff costs associated with these activities were estimated to be A$68,381; the cost per case detected was A$551 (Table 1 in online supplementary material).

### 3.4. Association of elevated Lp(a) with lipid phenotypes in adult relatives

Of the 83 probands, 43.4% had FCHL and 34.9% CH, the remaining having isolated elevated Lp(a) and unclassified mixed hyperlipidemia. There was no significant difference ($P = 0.449$) in the proportion of relatives identified with elevated Lp(a) from probands with FCHL (67.0%) and CH (77.4%) (Fig. 2 in online supplementary material). The concordance rate between the detection of Lp(a) $\geq 50$ mg/dL and the detection of FCHL among relatives of probands with FCHL was 34.8%, with a corresponding kappa statistic of 0.026. A low concordance rate was also observed with CH (53.2%, kappa coefficient 0.099). These data confirm the independent heritability of high Lp(a) and FCHL or CH (Table 1 in online supplementary material).

![Fig. 2. Examples of pedigrees with elevated lipoprotein(a); relatives were tested over 2-to 3 generations from probands with high lipoprotein(a) (see arrow).](image-url)
3.5. Characteristics of adult relatives according to Lp(a) concentration

Table 2 shows the characteristics of adult relatives according to their plasma Lp(a) concentrations. Relatives with Lp(a) between 50 and 99 mg/dL were significantly younger than those with Lp(a) ≥100 mg/dL (P < 0.05). Compared with relatives with Lp(a) <50 mg/dL, those with Lp(a) ≥100 mg/dL were more likely to have a family and personal history of CAD and be receiving treatment with cholesterol-lowering drugs. Plasma concentrations of pre-treatment cholesterol (P < 0.001), triglycerides (P < 0.05), non-HDL-cholesterol (P < 0.001), LDL-cholesterol (P < 0.001), apolipoprotein B and Lp(a) (P < 0.001) were also significantly higher in those with Lp(a) concentration ≥100 mg/dL compared with other groups. Relatives with Lp(a) concentration between 50 and 99 mg/dL had significantly higher LDL-cholesterol, apolipoprotein B and Lp(a) than those with Lp(a) <50 mg/dL (P < 0.05 for all). There were no significant differences in other variables among the groups (P > 0.05 for all).

3.6. Initiation of lipid-lowering therapy

Eighty-six of the relatives identified with Lp(a) ≥50 mg/dL were not on LLT (Table 2). Following participating in the Lp(a) detection program, 30.2% (n = 26) were initiated on LLT (Table 2 in online supplementary material). Further details of the characteristics of the relatives treated are given in supplementary material.

3.7. Participant reported experience of cascade testing

Of the 34 participants who completed the cascade testing questionnaire, 91.2% agreed they understood why they were approached for testing, 88.2% felt they were free to choose whether to participate in testing, 73.5% were satisfied with counselling received and 85.3% with the risk notification of result (Table 5 in online supplementary material).

4. Discussion

By contrast to previous reports, our study is the first to investigate the outcome of cascade testing for elevated Lp(a) from probands without a diagnosis of FH. Two previous studies have demonstrated the effectiveness of testing for elevated Lp(a) when genetic cascade testing for FH [12,13]. We have extended previous reports by confirming the value of cascade testing for elevated Lp(a) from probands who principally had common dyslipidemia that can mimic FH (i.e., FCHL and CH, both polygenic dyslipidemias).

4.1. Previous studies: familial hypercholesterolemia

By contrast to previous reports, our study is the first to investigate the outcome of cascade testing for elevated Lp(a) from probands without a diagnosis of FH. Two previous studies have demonstrated the effectiveness of testing for elevated Lp(a) when genetic cascade testing for FH [12,13]. We have extended previous reports by confirming the value of cascade testing for elevated Lp(a) from probands who principally had common dyslipidemia that can mimic FH (i.e., FCHL and CH, both polygenic dyslipidemias).

4.2. Detection and characteristics of relatives

The effectiveness of cascade testing in detecting elevated Lp(a) was underscored by our demonstration of an average of one new case of elevated Lp(a) per two relatives tested. This is consistent with the autosomal co-dominant heritability of Lp(a) that predicted in approximately 50% detection of elevated Lp(a) among relatives [10,14]. Consistent with previous reports [12,13], we found a higher proportion of relatives with high Lp(a) when testing from first-degree compared with second-degree relatives, although the population of relatives tested was relatively small. We also detected a higher proportion of relatives with elevated Lp(a) from probands with Lp(a) concentration >150 mg/dL than from probands with lower concentrations (i.e., between 100 and 150 mg/dL). These observations are compatible with the dilutional effect of the heritability of Lp(a) with an increase in separation of relatives from affected probands and with greater penetrance within families of genetic defects causative of high Lp(a) [e.g., copy number variation leading to smaller apo(a) isoform size] with probands with more severe elevation in Lp(a) [4,5,10].

Table 2

Comparison of demographic, clinical and biochemical characteristics of adult relatives tested for elevated lipoprotein(a).

| Lp(a) concentration | Adult Relatives with Lp(a) concentration | Number | Age (years) | Male, n (%) | Body mass index (kg/m²) | Family history of CAD, n (%) | Personal history of CAD, n (%) |
|---------------------|-----------------------------------------|--------|-------------|--------------|--------------------------|-----------------------------|-----------------------------|
| <50 mg/dL           | <50 mg/dL                                | 45     | 40.0 ± 4.0  | 16.8 ± 13.8  | 16 (35.6) ± 21 (48.8)    | 38 (84.4) ± 41 (95.3)       | 1 (2.2) ± 0 (0.0)            |
| 50 – 99 mg/dL       | 50 – 99 mg/dL                            | 43     | 37.0 ± 5.0  | 13.8 ± 13.0  | 21 (48.8) ± 27 (63.5)     | 41 (95.3) ± 41 (95.3)       | 0 (0.0) ± 0 (0.0)            |
| ≥100 mg/dL          | ≥100 mg/dL                               | 63     | 45.1 ± 15.7 | 25 (57.7) ± 25 (57.7) | 26.8 ± 4.9 ± 25.6 ± 3.9    | 63 (98.4) ± 7 (11.1)        | 7 (11.1) ± 7 (11.1)          |

P value:
- 0.023
- 0.335
- 0.015
- 0.094

ASCVD: atherosclerotic cardiovascular disease CAD: coronary artery disease, HDL: high-density lipoprotein, LDL: low-density lipoprotein, eGFR: estimated glomerular filtration rate.

Values represented as mean ± SD or geometric mean (95% confidence intervals) or number (%).

Bold P values are significant between groups by ANOVA or Chi-square, where appropriate.

1† Skewed variable with log transformation.
2‡ Five-year cardiovascular risk assessment in probands and adult relatives: Low <3%, Moderate 3 – 14%, and High >15%.

*P < 0.05 when compared with adult relatives with Lp(a) >100 mg/dL.
**P < 0.05; and ***P < 0.01 when compared with adult relatives with Lp(a) <50 mg/dL.
††P < 0.05.
† †††P < 0.01; and † † † †P < 0.001 when compared with the other two groups.
The cost per case detected was A$551. If applied nationwide, the marginal cost per index case would be A$824 (i.e., a total cost of $68,381 with 83 probands). Given a population prevalence of elevated Lp(a) of 20%, of whom 2% have been hitherto identified in Australia (current population 25.7 million), this gives a one-off cost of cascade testing all known cases (n = 102,760) of A$84,687 million in Australia. Assuming early diagnosis and effective management of elevated Lp(a) reduces ASCVD risk, this is likely to represent a cost-effective use of resources. However, this estimate does not include the costs prevented from downstream events, and hence may over-estimate the net cost of cascade testing. A more detailed cost-utility analysis is required.

Probands with high Lp(a) were identified from patients with common dyslipidemias, typically FCHL and CH. We found comparable detection rates of elevated Lp(a) among relatives of probands with FCHL or CH, both being polygenic disorders [15–17]. Accordingly, there was a poor agreement between the detection of FCHL (or CH) and elevated Lp(a) among the relatives. A similar discordance between FH and elevated Lp(a) was previously reported [12,13]. These data accord with the notion that the heritability of Lp(a) is distinct and independent of other dyslipidemias, including FH, FCHL and CH [12,13,15–17].

We found that compared with probands, adult relatives tested for elevated Lp(a) had an overall lower prevalence of symptomatic CAD, smoking, hypertension, and were less likely to be receiving cholesterol-lowering medication. This was anticipated because they were younger than probands. Among relatives without symptomatic CAD, the estimated 5-year risk of ASCVD was also lower in relatives with probands. It is noteworthy that, as with other methods assessing ASCVD risk, PREDICT does not include Lp(a) as a predictor variable [18]. Hence, this approach may not fully reflect the absolute risk of ASCVD in relatives detected with elevated Lp(a). Elevated Lp(a) has been recognized as a risk-enhancing factor for ASCVD risk [6–9]. Whether adding Lp(a) to the PREDICT algorithm can improve or reclassify estimated risk of ASCVD in relatives remains to be investigated, this being most relevant to those at moderate risk of ASCVD [19].

### 4.3. Initiation of lipid-lowering therapy in relatives

We showed that adult relatives with elevated Lp(a), particularly in those with Lp(a) ≥100 mg/dL, had a high frequency of smoking, hypertension, and dyslipidemia. This underscores the importance of lifestyle modification and LLT for mitigating modifiable cardiovascular risk in those who screen positive for Lp(a) [20]. We showed that among 30% of affected relatives initiated on LLT, there were clinically meaningful reductions in plasma concentrations of LDL-cholesterol and apoB-containing lipoproteins [21]. Beyond a higher Lp(a) concentration, those who started LLT were more likely to have FCHL, CH and a higher estimated absolute risk of ASCVD. Whether such changes in lipids and lipoproteins with treatment are associated with reductions in clinical outcomes remains to be determined. This information is important to inform the health economic assessment of cascade testing for Lp(a).

### 4.4. Strength and limitations: scope for further work

The strengths of our investigation include the use of a well-defined cohort of patients and a systematic approach to testing for elevated Lp(a), which was underpinned by previous experience with cascade testing for FH [12,13]. Based on a pilot study, we used a higher threshold of Lp(a) concentration ≥100 mg/dL in our study to define probands so as to enhance the detection rate of elevated Lp(a) among relatives. While ASCVD risk may begin at a threshold ≥30 mg/dL [2], our definition of elevated Lp(a) (i.e., ≥50 mg/dL) in relatives was based on current guidelines [6,8], corresponding to the 80th centile for Caucasian populations [6]. We carefully and phenotypically defined the dyslipidemias in our probands after excluding those with FH, noting FCHL and CH might have been more accurately defined using polygenic lipid scores [16,17]. The lack of a non-dyslipidemic control group is a potential limitation. However, we were limited to studying hyperlipidaemia, non-FH patients who were referred to our clinical service by their family doctors and other specialists.

The sample size of our probands was relatively small, implying that the precision of our estimates of the detection of relatives with elevated Lp(a) might have been compromised. However, we purposely selected probands for having higher levels of Lp(a) in order to increase the yield and effectiveness of detecting relatives with Lp(a) ≥ 50 mg/dL. A potential limitation is that we based Lp(a) cascade testing using measurement of Lp(a) mass concentration instead of genetic testing. However, the genetics of Lp(a) is complex and does not improve prediction of CAD beyond mass or molar concentrations [22]. Lp(a) is also on average a quantitative genetic trait that reflects the impact of multiple gene variants or copy number variations within the LPA locus [10]. We concluded that participants were generally satisfied with the cascade testing process but based this on a self-selected small sample size who responded reported to an online request and did not undertake a saturation analysis in the remainder of the study population; further refinement of pre-test counselling methods may be warranted. Our use of an apo(a) isoform sensitive immunoassay to quantitate Lp(a) mass, with potential bias from the effects of larger and smaller isoform sizes [23], is another limitation. However, a close correlation between this immunoassay and an isoform-independent LCMS method has been previously reported [24]. We did not adjust LDL-cholesterol concentration for Lp(a) cholesterol in our probands and relatives with elevated Lp(a), because there is no standard correction factor for making this adjustment [25]. We did not test the Lp(a) concentration of the spouses/partners of probands, because this is not part of usual practice in our clinic. However, among the progeny tested, we only found 7 individuals tested from 6 families with Lp(a) concentration greater than concentration of the affected parents, implying that at least 10% of spouses/partners would have Lp(a) ≥ 50 mg/dL. Hence, knowledge of elevated Lp(a) in spouses/partners of probands may provide further justification for testing for elevated Lp(a) in offsprings during cascade testing for elevated Lp(a). Nevertheless, as reported elsewhere [13], the expected prevalence of Lp(a) ≥ 50 mg/dL among relatives from index cases who do not have elevated Lp(a) is 17% [13]. This implies that, in the majority of patients detected in our program, elevated Lp(a) levels could be attributable to the penetrance of heritability of LPA genotype [smaller apo(a) isoform] from affected probands. Finally, we reported mainly on the outcomes of detection among adults with Lp(a), recommending that further studies should be carried out in children [26]. Our adult population was also mainly of Caucasian ancestry and further studies are also indicated in other ethnic groups, especially Southern Asian who may have a particularly high Lp(a) mediated risk of ASCVD [4,5,27].

### 5. Conclusion and clinical implications

Elevated Lp(a) is a common risk factor for ASCVD in the community, with one in 5 individuals having a plasma concentration ≥50 mg/dL [4,5]. Detecting affected people is a priority, as emphasized by current guidelines [6–9,27]. Selective, opportunistic, and universal screening approaches have been promulgated. By contrast to families with probands with FH and high Lp(a), in whom cascade testing would normally be carried out principally to detect FH, our study in patients without FH suggests that a separate model of care for identifying index cases with high Lp(a) to cascade test families needs to be developed. However, none of these approaches has hitherto been established and implemented. We show the potential value and cost of cascade testing from probands with high Lp(a) and how to make testing more effective. However, a formal cost utility evaluation of this approach to detecting high Lp(a) is required. The acceptability of screening for elevated Lp(a) needs to be confirmed with clear demonstration that interventions that lower elevated Lp(a) reduce clinical risk of ASCVD. Other than lipoprotein apheresis, there is no approved intervention for specifically lowering Lp(a) by a sufficient amount likely to have a major impact on...
major cardiovascular events [28]. However, a clinical trial is underway to test this hypothesis in high-risk individuals utilizing an anti-sense oligonucleotide targeted at the mRNA transcript of the apo(a) gene that decreases the hepatic production of Lp(a) particles (NCT04023552) [29]. A potent and more durable form of RNA therapeutics, utilizing the principle of small interfering RNA, has also recently been described [30]. At present, the value of screening for elevated Lp(a), including the cascade testing approach described in the present study, is to mitigate cardiovascular risk by addressing modifiable behavioural and clinical risk factors with established interventions, including use of statins, ezetimibe and proprotein convertase subtilisin/kevin type 9 (PCSK9) inhibitors [6,27].

Funding

The study was supported by a Raine Medical Research Foundation Grant. AC is supported by an Australian Government Research Training Program (RTP) Scholarship. JP is supported by National Health and Medical Research Council (NHMRC) Investigator Grant.

Author Contributions

GFW, DCC, KLE and JP designed the study. AC, JP, KLE, WB, AMW, MV and GFW conducted the study. AC, DCC, KLE, JP, RW, RN, EKM and GFW analysed the data. AC, DCC and GFW drafted the manuscript. All authors reviewed and approved the manuscript.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GFW has received honoraria for advisory boards and research grants from Amgen, Arrowhead, Esperion, AstraZeneca, Kowa, Novartis, Pfizer, Sanofi and Regeneron.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajpc.2022.100343.

References

[1] Kamstrup PR, Tybjærg Hansen A, Steffenensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 2331-9.
[2] Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302: 23.
[3] Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 23.
[4] Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2018;139: e1082-e1143. 2019.
[5] Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis 2019;291:62-70.
[6] Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 41:111–88. 2020.
[7] Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 41:111–88. 2020.
[8] Schmidt K, Noureen A, Kronenberg F, et al. Structure, function, and genetics of lipoprotein(a). J Lipid Res 2016;57:1399-59.
[9] Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014;8:390–400.
[10] Chakraborty A, Pang J, Chan DC, et al. Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolemia and elevated lipoprotein(a). Atherosclerosis 2021.
[11] Ellis KL, Perez de Isla L, Alonso R, et al. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol 2019;73: 1029–39.
[12] Utermann G, Menzel UJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;90:458-65.
[13] Ellis KL, Pang J, Chan DC, et al. Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: frequencies, associations and predictions. J Clin Lipidol 2016;10:1329-37.
[14] Trinder M, Vikulova D, Pimstone S, et al. Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. Atherosclerosis 2022;340:35–43.
[15] Shariff F, Putema M, Naie D, et al. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep 2019:21:43.
[16] Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400,000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391:1897-907.
[17] Verbeek R, Sandhu MS, Hovingh GK, et al. Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms. J Am Coll Cardiol 2017;69: 1513–5.
[18] Mullin B, Chan D, Charlesworth J, et al. Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a). Curr Opin Endocrinol Diabetes Obes 2021:28:174–80.
[19] Marston NA, Giugliano RF, Melliini GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerotic distinguishing between particle concentration, type, and content. JAMA Cardiol 2021:e215083.
[20] Page MM, Ellis KL, Pang J, et al. Coronary artery disease and the risk-associated LPA variants, rs10455872, in patients with suspected familial hypercholesterolemia. Clin Chim Acta 2020;510:211–5.
[21] Marovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res 2016;57:526-37.
[22] Golledge J, Rowbotham S, Velo R, et al. Association of serum lipoprotein (a) with adverse cardiovascular events in people with peripheral artery disease. J Am Heart Assoc 2020;9:e015355.
[23] Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein (a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021;62:100053.
[24] Wilson DP, Koschinsky ML, Moriarty PM. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). Curr Opin Endocrinol Diabetes Obes 2021:28:159–73.
[25] Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis 2022 Jan 19. https://doi.org/10.1016/j.pcad.2022.01.002. S0033-0620(22)00002-0Published ahead of print.
[26] Mullen B, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021;62:100053.
[27] Wilson DP, Koschinsky ML, Moriarty PM. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). Curr Opin Endocrinol Diabetes Obes 2021:28:159–73.
[28] Maden CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 mmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol 2020;40: 255–66.
[29] Tsitsikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a). J Am Coll Cardiol 2021;77:1756–89.
[30] Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 2022;28:96.